MICHELLE WALKER: Open Payments
NPI 1235368291 · HAGERSTOWN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$630 in 13 payments from 11 companies in 2025. Trend: 2023 $1,208 · 2024 $989 · 2025 $630
Food & beverage: $630
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 1 | $138 |
| E.R. Squibb & Sons, L.L.C. | 1 | $135 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| Novo Nordisk Inc | 2 | $46 |
| AstraZeneca Pharmaceuticals LP | 2 | $40 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $34 |
| LEO Pharma Inc. | 1 | $25 |
| ABBVIE INC. | 1 | $24 |
| Corium, LLC | 1 | $22 |
| Abbott Laboratories | 1 | $21 |
Products named: INGREZZA, COBENFY, Auvelity, Rybelsus, AIRSUPRA, CAPLYTA, ADBRY, VRAYLAR.
Industry payments across MD — which companies pay providers there.
